ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 905

First Step in the Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis: A Data Driven Approach

Anna-Birgitte Aga1, Hilde Berner Hammer2, Inge C. Olsen1, Till Uhlig2, Tore K. Kvien3, Désirée van der Heijde4, Elisabeth Lie3, Espen A. Haavardsholm5 and the Arctic study Group5, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound

Session Type: Abstract Submissions (ACR)

Background/Purpose

The use of ultrasonography (US) in rheumatoid arthritis (RA) is rapidly increasing. Currently, there is no consensus regarding which joints and tendons should be systematically assessed. Validity, including comprehensiveness, and responsiveness must be weighted against feasibility. Our objectives were to develop candidate sets for assessment of US joint inflammation through a data driven approach using data from early RA patients, and then perform initial validation in an established RA cohort.

Methods

Between January 2010 and June 2013 patients (pts) were included in one of two cohorts: Early RA (DMARD-naïve pts with RA of <2 yrs symptom duration fulfilling 2010 ACR/EULAR classification criteria), and established RA (pts starting or switching biologic DMARDs). An extensive US examination was performed by experienced sonographers using a validated grey-scale (GSUS) and power Doppler (PDUS) semi-quantitative scoring system with scores 0-3 for GSUS and PDUS in each of the following 36 joints and 4 tendons: MCP 1-5, PIP 2-3, radiocarpal, distal radioulnar, intercarpal, elbow, knee, talocrural, MTP 1-5, extensor carpi ulnaris and tibialis posterior tendons, bilaterally. An US atlas was used as reference1. We performed principal component factor analyses (PCA) in the early RA US data to identify joint groups with high internal correlation, and selected candidate joint/tendon sets based on these analyses. We assessed the loss of information compared to the full score by R2 from linear regression analysis. Finally, the candidate sets were validated in the established RA cohort.

Results

A total of 439 patients were included, 227 with early and 212 with established RA; 62% vs. 77% anti-CCP pos, mean(SD) age 51(14) vs. 52(13) yrs, DAS28 4.7(1.2) vs. 4.7(1.4), median(25-75 percentile) 28-SJC 6(3-11) vs. 5(2-10), disease duration 0.5(0.2-0.9) vs. 8(3-15) yrs, mean(95% CI) 36-joint GSUS score 23(21-25) vs. 28(25-30) (p=0.003), 36-joint PDUS score 11(10-12) vs. 13(11-15) (p=0.20). Nearly 17,000 individual joints/tendons were assessed. We identified 9 groups based on PCA in the early RA data, presented in table 1. Comparisons between the candidate sets and the total GSUS and PDUS scores in the early RA cohort as well as validation in the established RA cohort are presented in table 2.

Conclusion

We used a data driven approach to develop candidate sets of joints/tendons to be assessed by GS and PD US, and the resulting reduced scores retained most of the information from the total score of 40 joints/tendons. Unilateral reduced scores explained 78% to 85% of the total score, while bilateral reduced scores explained 89% to 93% of the total score. The candidate scores performed equally well in a validation cohort of established RA. Our results show that a reduced US assessment may efficiently contribute to disease assessment in RA. Further validation in longitudinal RA cohorts and data on responsiveness are needed.

1Hammer HB et al. ARD 2011

Table 1: 9 joint/tendon groups with correlating scores based on principal component factor analysis of the GSUS and PDUS scores in early RA

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Group 8

Group 9

MTP 2

MTP 3

MTP 4

MTP 5

Radiocarpal

Intercarpal

Radioulnar

MCP 2

MCP 3

MCP 4

MCP 5

PIP 2

PIP 3

Elbow

Tib.post. tendon

MTP 1

Ext.carpi ulnaris tendon

MCP 1

Table 2: Comparison of candidate joint/tendon sets for GSUS and PDUS assessment and the full 40-joint/tendon score in the early and established RA cohorts

Modality

Candidate set of US joint inflammation

Side

Number of joints/tendons

Early RA

Established RA

Fraction of information in total score explained3

Fraction of information in total score explained3

GSUS

A1

Right

9

0.79

0.79

Left

9

0.83

0.81

Bilateral

18

0.89

0.91

B2

Right

11

0.85

0.85

Left

11

0.85

0.86

Bilateral

22

0.93

0.94

PDUS

A1

Right

9

0.78

0.78

Left

9

0.78

0.81

Bilateral

18

0.89

0.91

B2

Right

11

0.83

0.85

Left

11

0.81

0.84

Bilateral

22

0.92

0.95

1MCP 1, MCP 2, PIP 3, radiocarpal, elbow, MTP 1, MTP 2, and extensor carpi ulnaris and tibialis posterior tendons

2Same as candidate set A with addition of MCP 5 and MTP 5

3Linear regression analysis with the total US score as dependent variable and the sum score of the candidate sets as independent variable

GSUS = gray-scale ultrasonography. PDUS = power Doppler ultrasonography.


Disclosure:

A. B. Aga,
None;

H. B. Hammer,

AbbVie,

2;

I. C. Olsen,
None;

T. Uhlig,
None;

T. K. Kvien,
None;

D. van der Heijde,
None;

E. Lie,
None;

E. A. Haavardsholm,

AbbVie, Pfizer, MSD, Roche, UCB,

2;

T. A. study Group,

AbbVie, Pfizer, MSD, Roche, UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/first-step-in-the-development-of-an-ultrasound-joint-inflammation-score-for-rheumatoid-arthritis-a-data-driven-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology